Get started
UroGen Pharma Ltd.UroGen Pharma Ltd.UroGen Pharma Ltd.

UroGen Pharma Ltd.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

URGN chart


Full chart

URGN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪511.46 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.14 USD
Net income (FY)
‪−102.24 M‬ USD
Revenue (FY)
‪82.71 M‬ USD
Shares float
‪38.27 M‬
Beta (1Y)
1.34

Employees


Employees (FY)
201
Change (1Y)
+1 +0.50%
Revenue / Employee (1Y)
‪411.51 K‬ USD
Net income / Employee (1Y)
‪−508.68 K‬ USD

About UroGen Pharma Ltd.


Sector
Health Technology
Industry
Biotechnology
CEO
Elizabeth Barrett
Website
urogen.com
Headquarters
Princeton
Founded
2004
ISIN
IL0011407140
FIGI
BBG00GFCC613
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

URGN news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of URGN is 12.12 USD — it has increased by 0.17% in the past 24 hours. Watch UroGen Pharma Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange UroGen Pharma Ltd. stocks are traded under the ticker URGN.
URGN stock has fallen by −1.70% compared to the previous week, the month change is a −6.77% fall, over the last year UroGen Pharma Ltd. has showed a 3.15% increase.
We've gathered analysts' opinions on UroGen Pharma Ltd. future price: according to them, URGN price has a max estimate of 64.00 USD and a min estimate of 22.00 USD. Watch URGN chart and read a more detailed UroGen Pharma Ltd. stock forecast: see what analysts think of UroGen Pharma Ltd. and suggest that you do with its stocks.
URGN reached its all-time high on May 21, 2018 with the price of 69.57 USD, and its all-time low was 4.85 USD and was reached on May 25, 2022. View more price dynamics on URGN chart.
See other stocks reaching their highest and lowest prices.
URGN stock is 3.10% volatile and has beta coefficient of 1.34. Track UroGen Pharma Ltd. stock price on the chart and check out the list of the most volatile stocks — is UroGen Pharma Ltd. there?
Today UroGen Pharma Ltd. has the market capitalization of ‪511.46 M‬, it has increased by 1.32% over the last week.
Yes, you can track UroGen Pharma Ltd. financials in yearly and quarterly reports right on TradingView.
UroGen Pharma Ltd. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
URGN earnings for the last quarter are −0.55 USD per share, whereas the estimation was −0.82 USD resulting in a 32.69% surprise. The estimated earnings for the next quarter are −0.72 USD per share. See more details about UroGen Pharma Ltd. earnings.
UroGen Pharma Ltd. revenue for the last quarter amounts to ‪25.20 M‬ USD, despite the estimated figure of ‪24.20 M‬ USD. In the next quarter, revenue is expected to reach ‪26.13 M‬ USD.
URGN net income for the last quarter is ‪−23.67 M‬ USD, while the quarter before that showed ‪−33.40 M‬ USD of net income which accounts for 29.13% change. Track more UroGen Pharma Ltd. financial stats to get the full picture.
No, URGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 11, 2024, the company has 201.00 employees. See our rating of the largest employees — is UroGen Pharma Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. UroGen Pharma Ltd. EBITDA is ‪−82.43 M‬ USD, and current EBITDA margin is −77.17%. See more stats in UroGen Pharma Ltd. financial statements.
Like other stocks, URGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade UroGen Pharma Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So UroGen Pharma Ltd. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating UroGen Pharma Ltd. stock shows the sell signal. See more of UroGen Pharma Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.